Actively Recruiting
Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)
Led by Auburn University · Updated on 2025-02-27
40
Participants Needed
1
Research Sites
138 weeks
Total Duration
On this page
Sponsors
A
Auburn University
Lead Sponsor
I
Indiana University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Compared with White Adults, Non-Hispanic Black Adults are at an elevated risk of developing cardiovascular disease (CVD) and end stage chronic-kidney disease (CKD), two of the leading causes of death in the United States. Inadequate hydration status is associated with risk factors for both CVD and CKD. Prior data show that Black individuals are less likely to be adequately hydrated when compared with their White counterparts. Further, socioeconomic factors have been shown to influence hydration practices. Inadequate hydration influences certain hormones that regulate blood volume and impact blood pressure, but increasing potassium intake may provide some positive effects on normalizing these hormones and blood pressure. Black adults, in particular, are more likely to consume less potassium, have inadequate hydration, and tend to have higher blood pressure. As such, there is a critical need for effective strategies to address racial disparities in hydration and resultant health consequences; as well as establish the role of socioeconomic factors contributing to hydration. Therefore, the investigators are seeking to test the investigators' central hypothesis that water with a potassium supplement will improve hydration and cardiovascular health in young White adults (n = 20, 10 females, 10 males), and to a greater extent in young Black Adults (n = 20, 10 females, 10 males. The investigators will assess measures of blood pressure, arterial stiffness, and biomarkers in the urine and blood samples prior to and following a 14-day hydration intervention of 1) bottled water and 2) bottled water with potassium supplementation (2000mg potassium/day).
CONDITIONS
Official Title
Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between the ages of 18-30 years
- Resting blood pressure no higher than 150/90 mmHg
- BMI below 35 kg/m2
- Free of metabolic disease such as diabetes, kidney disease, pulmonary disorders like COPD, cardiovascular disease including peripheral vascular, cardiac, or cerebrovascular, autoimmune diseases, and no history of cancer
You will not qualify if you...
- Have medical conditions or take medications that prevent giving blood (e.g., hemophilia, Pradaxa, Eliquis)
- Currently pregnant or trying to become pregnant
- Taking medications contraindicated with potassium supplementation, including RAAS blockers (Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan)
- Using non-steroidal anti-inflammatory drugs (Aspirin, Ibuprofen, Naproxen)
- Using non-selective beta-blockers (Pindolol, Penbutolol, Oxprenolol, Propranolol, Nadolol, Sotalol, Timolol, Tertatolol)
- Taking calcineurin inhibitors like Cyclosporine
- Using Heparin or other blood thinning medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kinesiology Building
Auburn, Alabama, United States, 36849
Actively Recruiting
Research Team
N
Nina L Stute, M.S.
CONTACT
M
Meral A Culver, M.S.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here